We developed a cardiac multi-oblique-slice T1-mapping sequence,
called Tmax, for simultaneous in vivo
cardiac and multi-region T1-mapping in rats. We
validated Tmax with gadolinium contrast agent (CA) scans then applied it to support our concurrent development of a reactive
oxygen species activated T1-shortening agent, called H4qtp2, in doxorubicin-treated (Dox) rats. The new Tmax sequence performed excellent at simultaneously
quantifying gadolinium T1 effects in cardiac and renal regions. However, application of Tmax with low dose
levels of H4qtp2 CA in Dox rats gave marginal results from
too low dose of H4qtp2 to sufficiently affect
the T1 and quantify Dox-induced pathology
This abstract and the presentation materials are available to members only; a login is required.